Compounds > cabergoline
Page last updated: 2024-08-23

cabergoline and Albright Syndrome

cabergoline has been researched along with Albright Syndrome in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asha, HS; Cherian, KE; Paul, TV; Rajan, R1
Albuquerque, LA; Almeida, JP; Ferraz, CL; Ferraz, TM; Gondim, J; Mota, I1
Akintoye, SO; Bianco, P; Booher, S; Chebli, C; Cherman, N; Collins, MT; Feuillan, P; Kushner, H; Leroith, D; Robey, PG; Wientroub, S1
Fujieda, K; Ishi, N; Ishizu, K; Jo, W; Tajima, T; Tsubaki, J1

Other Studies

4 other study(ies) available for cabergoline and Albright Syndrome

ArticleYear
McCune Albright syndrome: an endocrine medley.
    BMJ case reports, 2019, Jul-15, Volume: 12, Issue:7

    Topics: Adenoma; Bone Density Conservation Agents; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Female; Fibrous Dysplasia, Polyostotic; Humans; Hyperthyroidism; Leg; Musculoskeletal Pain; Pituitary Neoplasms; Rare Diseases; Young Adult; Zoledronic Acid

2019
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
    Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:1

    Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Ergolines; Facial Bones; Female; Fibrous Dysplasia, Polyostotic; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Pituitary Neoplasms; Skull

2009
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
    The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:11

    Topics: Adenoma; Antineoplastic Agents; Body Height; Cabergoline; DNA Mutational Analysis; Ergolines; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits, Gs; Human Growth Hormone; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms

2002
Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
    Endocrine journal, 2008, Volume: 55, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Cabergoline; Delayed-Action Preparations; Ergolines; Fibrous Dysplasia, Polyostotic; Gigantism; Humans; Male; Octreotide; Radiography

2008